STOCK TITAN
  1. Home
  2. Sec-filings
  3. MYNZ
  4. [Form 3] MAINZ BIOMED N.V. Initial Statement of Beneficial Ownership

Mainz Biomed (MYNZ) director Gregory Tibbitts details option stakes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Mainz Biomed N.V. director Gregory J. Tibbitts filed an initial Form 3 showing his beneficial holdings in the company’s securities as of 01/01/2026. He reports holding no ordinary shares directly, but does hold employee stock options over ordinary shares. One option grant covers 10,000 ordinary shares at an exercise price of $4.95, with 50% vested on 03/04/2025 and the remaining 25% tranches vesting on 03/24/2026 and 03/04/2027. He also holds fully vested options for 625 ordinary shares at $356.4 and 250 ordinary shares at $302.8, all owned directly.

Positive

  • None.

Negative

  • None.
Insider Tibbitts Gregory J
Role Director
Type Security Shares Price Value
holding Employee Stock Option (Right to Buy) -- -- --
holding Employee Stock Option (Right to Buy) -- -- --
holding Employee Stock Option (Right to Buy) -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Employee Stock Option (Right to Buy) — 10,875 shares (Direct); Ordinary Shares — 0 shares (Direct)
Footnotes (2)
  1. F1. 50% of the option vested upon grant on 03/04/2025; the remaining balance vests 25% on 03/24/26 and 25% on 03/04/2027.
  2. F2. Fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does Mainz Biomed (MYNZ) disclose in this Form 3?

The filing shows director Gregory J. Tibbitts’ initial statement of beneficial ownership, listing his Mainz Biomed ordinary share and stock option positions as of 01/01/2026.

How many Mainz Biomed ordinary shares does Gregory Tibbitts own directly?

The Form 3 reports that he beneficially owns 0 ordinary shares directly.

What stock options does Gregory Tibbitts hold in Mainz Biomed (MYNZ)?

He holds employee stock options over 10,000, 625, and 250 Mainz Biomed ordinary shares, all reported as directly owned derivative securities.

What are the exercise prices of Gregory Tibbitts’ Mainz Biomed stock options?

The options have exercise prices of $4.95 for 10,000 shares, $356.4 for 625 shares, and $302.8 for 250 shares.

How do the vesting terms work for the 10,000-share Mainz Biomed option grant?

According to the footnote, 50% of the 10,000-share option vested on 03/04/2025, with the remaining balance vesting 25% on 03/24/2026 and 25% on 03/04/2027.

Are any of Gregory Tibbitts’ Mainz Biomed options already fully vested?

Yes. The options covering 625 and 250 ordinary shares are described in the footnote as fully vested.

What is Gregory Tibbitts’ role at Mainz Biomed (MYNZ)?

The Form 3 identifies him as a director of Mainz Biomed N.V. and not a 10% owner or officer.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Tibbitts Gregory J
(Last) (First) (Middle)
MAINZ BIOMED N.V.
ROBERT KOCH STRASSE 50
(Street)
MAINZ 2M 55129
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2026 		3. Issuer Name and Ticker or Trading Symbol
MAINZ BIOMED N.V. [ MYNZ ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares 0 D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy) 03/04/2025 (1) Ordinary Shares 10,000 $4.95 D
Employee Stock Option (Right to Buy) 06/15/2022 (2) Ordinary Shares 625 $356.4 D
Employee Stock Option (Right to Buy) 12/21/2022 (2) Ordinary Shares 250 $302.8 D
Explanation of Responses:
1. 50% of the option vested upon grant on 03/04/2025; the remaining balance vests 25% on 03/24/26 and 25% on 03/04/2027.
2. Fully vested.
/s/ Gregory Tibbits 01/26/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR